1. Home
  2. ANNX vs PBPB Comparison

ANNX vs PBPB Comparison

Compare ANNX & PBPB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • ANNX
  • PBPB
  • Stock Information
  • Founded
  • ANNX 2011
  • PBPB 1977
  • Country
  • ANNX United States
  • PBPB United States
  • Employees
  • ANNX N/A
  • PBPB N/A
  • Industry
  • ANNX Biotechnology: Pharmaceutical Preparations
  • PBPB Restaurants
  • Sector
  • ANNX Health Care
  • PBPB Consumer Discretionary
  • Exchange
  • ANNX Nasdaq
  • PBPB Nasdaq
  • Market Cap
  • ANNX 216.1M
  • PBPB 305.0M
  • IPO Year
  • ANNX 2020
  • PBPB 2013
  • Fundamental
  • Price
  • ANNX $2.12
  • PBPB $10.62
  • Analyst Decision
  • ANNX Strong Buy
  • PBPB Strong Buy
  • Analyst Count
  • ANNX 4
  • PBPB 3
  • Target Price
  • ANNX $12.50
  • PBPB $15.33
  • AVG Volume (30 Days)
  • ANNX 1.3M
  • PBPB 186.6K
  • Earning Date
  • ANNX 05-12-2025
  • PBPB 05-07-2025
  • Dividend Yield
  • ANNX N/A
  • PBPB N/A
  • EPS Growth
  • ANNX N/A
  • PBPB 1009.90
  • EPS
  • ANNX N/A
  • PBPB 1.39
  • Revenue
  • ANNX N/A
  • PBPB $465,126,000.00
  • Revenue This Year
  • ANNX N/A
  • PBPB $4.74
  • Revenue Next Year
  • ANNX N/A
  • PBPB $4.48
  • P/E Ratio
  • ANNX N/A
  • PBPB $7.61
  • Revenue Growth
  • ANNX N/A
  • PBPB N/A
  • 52 Week Low
  • ANNX $1.29
  • PBPB $6.28
  • 52 Week High
  • ANNX $7.85
  • PBPB $13.48
  • Technical
  • Relative Strength Index (RSI)
  • ANNX 56.77
  • PBPB 66.51
  • Support Level
  • ANNX $1.92
  • PBPB $9.75
  • Resistance Level
  • ANNX $2.21
  • PBPB $10.80
  • Average True Range (ATR)
  • ANNX 0.17
  • PBPB 0.29
  • MACD
  • ANNX 0.03
  • PBPB 0.05
  • Stochastic Oscillator
  • ANNX 77.59
  • PBPB 82.86

About ANNX Annexon Inc.

Annexon Inc is a clinical-stage biopharmaceutical company developing a pipeline of novel therapies for patients with classical complement-mediated disorders of the body, brain, and eye. Its pipeline is based on its platform technology addressing well-researched classical complement-mediated autoimmune and neurodegenerative disease processes, both of which are triggered by aberrant activation of C1q. Its pipeline of product candidates is designed to block the activity of C1q and the entire classical complement pathway in a broad set of complement-mediated diseases. Its product candidates are ANX005, for autoimmune & neurodegenerative disorders; ANX007, for neurodegenerative ophthalmic disorders; ANX1502 for Oral small molecule; and ANX009, for systemic autoimmune diseases.

About PBPB Potbelly Corporation

Potbelly Corp owns and franchises hundreds of limited-service restaurants specializing in sandwiches and salads, shakes. The menu includes toasty sandwiches, signature salads, soups, chili, sides, desserts, and, in breakfast locations it serves breakfast sandwiches and steel-cut oatmeal. majority of its locations are company-owned and located in the United States, with Illinois and Texas housing far more locations than any other state. The company has franchise partners in a number of countries. Excluding the United States, its franchises are in the Middle East.

Share on Social Networks: